Mirabegron and Slow speech - a phase IV clinical study of FDA data

Summary:

Slow speech is reported as a side effect among people who take Mirabegron (mirabegron), especially for people who are female, 50-59 old, also take Hydrochlorothiazide, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Slow speech when taking Mirabegron. It is created by eHealthMe based on reports of 5,378 people who have side effects when taking Mirabegron from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Slow speech?

Slow speech is found to be associated with 274 drugs and 409 conditions by eHealthMe. Check the latest studies of Slow speech.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

5,378 people reported to have side effects when taking Mirabegron.
Among them, 14 people (0.26%) have Slow speech.

Among these 14 people:

What is the gender of people who have Slow speech when taking Mirabegron? *

female: 92.86 %
male: 7.14 %

What is the age of people who have Slow speech when taking Mirabegron? *

What are other drugs people take besides Mirabegron? *

What are other side effects people have besides Slow speech? *

Speech Impairment (Adult) (inability to speak (adult)): 12 people, 85.71%
Weakness: 10 people, 71.43%
Headache (pain in head): 9 people, 64.29%
Indigestion: 9 people, 64.29%
Muscle Aches (muscle pain): 9 people, 64.29%
Neck Pain: 9 people, 64.29%
Balance Disorder: 9 people, 64.29%
Lip Disorder (disease of lip): 9 people, 64.29%
High Blood Pressure: 9 people, 64.29%
Glossodynia (a burning or painful sensation in the tongue): 9 people, 64.29%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 50.00%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 3 people, 21.43%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 21.43%
Headache (pain in head): 3 people, 21.43%
Parkinson's Disease: 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and have Slow speech?

- Check whether Slow speech is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mirabegron:

Mirabegron (5,414 reports)

Slow speech treatments and more:

Slow speech (2,496 reports)

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Slow speech:

Slow speech (274 drugs)

Browse all the conditions that are associated with Slow speech:

Slow speech (409 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron (the active ingredients of Mirabegron) and Mirabegron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.